TABLE 1.

Clinical and demographic characteristics of the study population, including presenting symptoms, grade, stage, treatment, and clinical outcome to date

Case No.	Gender	Age at Diagnosis (yrs)	Presenting Symptom	Grade (Hyams)	Stage (Kadish)	Treatment	Clinical Outcome
1	F	68	Hyposmia, refractory sinonasal symptoms	II	C → D; nodal metastases identified 30 mos post–initial resection	Surgery & adjuvant CCRT (6900 cGy in 33 fractions)	Bilateral metastatic cervical adenopathy receiving octreotide LAR (26 mos of therapy; 68 mos post–initial surgery)
2	F	53	Unilateral periorbital swelling	IV	D	Surgery & adjuvant CCRT (6600 cGy in 30 fractions)	Recurrent metastatic CNS disease w/in 6 mos of completing CCRT
3	F	64	Dysphonia	I–II	C	Surgery & adjuvant RT (6120 cGy in 34 fractions)*	Deceased (11 mos post–initial surgery); no evidence of disease (27 mos post–initial surgery)
4	F	59	Unilateral nasal congestion/obstruction	II	B	Surgery	No evidence of disease (10 mos post–initial surgery)
5	M	65	Anosmia	II	Nodal metastases identified 33 mos post–initial resection	C → D; surgery & bilateral neck RT (6000 cGy in 30 fractions)	Recurrent metastatic disease (dural, osseous, parapharyngeal space) receiving [177Lu]-DOTATATE (3 of 4 doses received) & octreotide LAR treatment (83 mos post–initial surgery)

^*Terminated chemotherapy due to side effects.